arXiv:2606. 19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions.
arXiv:2512. 11682v2 Announce Type: replace Abstract: Therapeutic decision-making in clinical medicine constitutes a high-stakes domain in which AI guidance interacts with complex interactions among patient characteristics, disease processes, and pharmacological agents.
The paper introduces an LLM-as-a-Judge framework for evaluating the outputs of an agentic drug discovery assistant, ChatInvent, deployed at AstraZeneca. It defines four quality dimensions—Completeness, Relevancy, Structural Clarity, and Scope Adherence—alongside deterministic Tool Call Correctness checks, and validates the judge against five expert annotators. After optimizing the best-performing judge with few-shot demonstrations, alignment with human majority votes improves from 0.80 to 0.86, and the framework reveals that informal question phrasing does not degrade output quality.
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
OpenDiscoveryTrace is a public dataset of 558 complete AI scientific agent trajectories that records the reasoning process—thoughts, tool calls, observations, errors, revision triggers, and confidence—across 124 scientific tasks in drug discovery, materials science, genomics, and literature analysis. The dataset includes seven models (three frontier models and four open‑weight models) and 60 live‑retrieval variants, providing a balanced view of performance and error patterns. Pilot analysis shows that process traces reveal behavioral differences invisible to output‑only evaluation, such as differing error rates and types among frontier models.
arXiv:2608. 06961v1 Announce Type: new Abstract: Early-stage molecular design is an iterative process, not just a task of generating molecules.
arXiv:2502. 18864v2 Announce Type: replace Abstract: Scientific discovery is driven by scientists generating novel hypotheses for complex problems that undergo rigorous experimental validation.
arXiv:2606. 28692v1 Announce Type: new Abstract: Treatment reasoning underpins every therapeutic decision, integrating disease context, comorbidities, medications, contraindications, and evolving biomedical knowledge to select an appropriate therapy.
arXiv:2408. 13378v5 Announce Type: replace Abstract: Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature.
arXiv:2604. 26498v3 Announce Type: replace Abstract: The rapid growth of molecular foundation models and large language models (LLMs) has encouraged a scale centred view of AI in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models.
arXiv:2608. 11483v1 Announce Type: new Abstract: Hit-to-lead optimization requires iterative design of hit analogs across competing potency, selectivity, physicochemical, pharmacokinetic, safety, and synthetic constraints.
arXiv:2608. 11341v1 Announce Type: new Abstract: Apollo did not reach the Moon merely because its engineers could solve difficult equations.
arXiv:2606. 00555v1 Announce Type: new Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together.